Amantadine in parkinson’s disease: modern possibilities of long-term therapy
https://doi.org/10.21518/2079-701X-2018-9-34-38
Abstract
The long-term therapy of Parkinson’s disease (PD) with dopaminergic drugs is naturally accompanied by the fluctuations in symptoms and dyskinesia, and these complications are an extremely important factor that adversely affects the quality of life. The hyperactivity of glutamate NMDA receptors of the striatum plays an important role in the pathophysiology of medicinal dyskinesia, so the use of anti-glutamatergic agents, primarily amantadine, is currently the common method of combating dyskinesia. This article summarizes the current understanding of the mechanisms of action and the clinical effects of amantadine derivatives in patients with different stages of PD, with an emphasis on the antidiskinetic effect of this group of antiparkinsonian agents. It also presents the advantages of amantadine sulphate (PK-Merz) over other dosage forms (pharmacokinetics, duration of effect, tolerability, possibility of intravenous infusion administration), including those in the treatment of acute decompensation of PD.
About the Authors
V. V. Poleshchuk
Scientific Center of Neurology, Federal State Budgetary Research Institute
Russian Federation
Russian Federation
Moscow
S. N. Illarioshkin
Scientific Center of Neurology, Federal State Budgetary Research Institute
Russian Federation
Russian Federation
Moscow
References
1. Parkinson J. An essay on the shaking palsy. London: Sherwood, 1817.
2. Jenner P, Morris HR, Robbins TW et al. Parkinson’s disease – the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J Park Dis, 2013, 3: 1–11.
3. Poewe W, Seppi K, Tanner CM. Parkinson disease. Nat Rev Dis Primers, 2017, 3: 17013.
4. Litvinenko IV. Parkinson’s disease. M: Miklos, 2006
5. Olanow CW, Schapira AHV. Therapeutic prospects for Parkinson disease. Ann Neurol, 2013, 74: 337–347.
6. Levin OS, Fedorova NV. Parkinson’s disease. М.: MEDpress-inform, 2014.
7. Fahn S, Poewe W. Levodopa: 50 years of a revolutionary drug for Parkinson disease. Mov Disord, 2015, 30: 1–3.
8. Hornykiewicz O. L-DOPA. J Parkinson’s Dis, 2017, 7: 3–10.
9. Guidance on the diagnosis and treatment of Parkinson’s Disease (edited by Illarioshkina SN, Levin OS). М.: MEDPRESSINFORM, 2016.
10. Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of nondopaminergic treatments. J Neurol, 2000, 247(Suppl.2): II43–II50.
11. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol, 2006, 63: 1756–1760.
12. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson’s disease. Adv Neurol, 1996, 69: 497–501.
13. Nodel MR, Yakhno NN. Motor fluctuations and dyskinesia in Parkinson’s disease: new therapeutic options. Nevrologicheskiy Zhurnal, 2007, 2: 26-33.
14. Illariyoshkin SN, Fedotova EYu, Seliverstov YuA. Modern high-tech treatments for Parkinson’s disease. In the book: Brain Diseases - Medical and Social Aspects (edited by Gusev EI, Gekht AB). Moscow: Buki-Vedi, 2016: 543-552.
15. Brotchie JM, Lee J, Venderova K. Levodopainduced dyskinesia in Parkinson’s disease. J Neural Transm, 2005, 112: 359–391.
16. Schapira A. Present and future drug treatment for Parkinson’s disease. J Neurol Neurosurg Psychiatry, 2005, 76: 1472–1478.
17. Illariyoshkin SN. Derivatives of amantadine in the treatment of Parkinson’s disease. Nervnye Bolezni, 2016, 3: 14-19
18. Cersósimo MG, Micheli FE. Antiglutamatergic drugs in the treatment of Parkinson’s disease. In: C. Koller, E. Melamed (eds). Handbook of Clinical Neurology, Vol. 84: Parkinson’s disease and related disorders. Part II. Elsevier, 2007: 127–136.
19. Schwab RS, England AC, Poskanzer DC et al. Amantadine in the treatment of Parkinson’s disease. JAMA, 1969, 208: 1168–1170.
20. Stoof JC, Booij J, Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications. Clin Neurol Neurosurg, 1992, 94: 4–6.
21. Kornhuber J, Quack G, Danysz W et al. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology, 1995, 34: 713–721.
22. Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinson’s disease. A double blind, placebo controlled, crossover study with long term follow up. Neurology, 1975, 25: 603–606.
23. Schwab RS, England AC, Poskanzer DC et al. Amantadine in the treatment of Parkinson’s disease. JAMA, 1969, 208: 1168–1170.
24. Fahn S, Isgreen WP. Long term evaluation of amantadine and levodopa combination in parkinsonism by double blind crossover analysis. Neurology, 1975, 25: 695–700.
25. Savery F. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson’s disease. Dis Nerv Syst, 1977, 38: 605–608.
26. Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs, 2007, 21: 677–692.
27. Elahi B, Phielipp N, Chen R. N-methyl-Daspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J Neurol Sci, 2012, 39: 465–472.
28. Oertel WH, Quinn NP. Parkinson’s disease: drug therapy. Baillieres Clin Neurol, 1997, 6: 89–108.
29. Metman VL, Del Dotto P, van den Munckhof P et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology, 1998, 50: 1323–1326.
30. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord, 1998, 13: 798–802.
31. Da Silva-Junior FP, Braga-Neto P, Sueli Monte F, De Bruin VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord, 2005, 11: 449–452.
32. Luginger E, Wenning GK, Boesch S, Poewe W. Beneficial effects of amantadine on L-dopainduced dyskinesias in Parkinson’s disease. Mov Disord, 2000, 15: 873–878.
33. Rajput AH, Rajput A, Lang AE et al. New use for an old drug: amantadine benefits levodopa induced dyskiensias. Mov Disord, 1998, 13: 851–854.
34. Ruicka E, Streiova H, Jech R et al. Amantadine infusion treatment of motor fluctuations and dyskinesias in Parkinson’s disease. J Neural Transm, 2000, 102: 1297–1306.
35. Del Dotto P, Pavese N, Gambaccini G et al. Intravenous amantadine improves levadopainduced dyskinesias: an acute double-blind placebo-controlled study Mov Disord, 2001, 16: 515–520.
36. Metman VL, Del Dotto P, Lepoole K et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol, 1999, 56: 1383–1386.
37. Thomas A, Iacono D, Luciano AL et al. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry, 2004, 75: 141–143.
38. Wolf E, Seppi K, Katzenschlager R et al. Longterm antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord, 2010, 25: 1357–1363.
39. Grachev IS, Fedorova NV. Medicinal dyskinesia in Parkinson’s disease: classification, impact on quality of life and approaches to treatment. In the collection of works: Parkinson’s disease and movement disorders. A guide for practitioner on the materials of the First National Congress (edited by Illarionkina SN, Yakhno NN). M.: 2008: 88-92.
40. Ilzenberg R, Bonuccelli U, Schechtman E et al. Association between amantadine and the onset of dementia in Parkinson’s disease. Mov Disord, 2006, 21: 1375–1379.
41. Uitti RJ, Rajput AH, Ahlskog JE et al. Amantadine treatment as an independent predictor of improved survival in Parkinson’s disease. Neurology, 1996, 46: 1551–1552.
42. Mizuno Y, Takubo H, Mizuta E, Kuno S. Malignant syndrome in Parkinson’s disease: concept and review of the literature. Parkinsonism Relat Disord, 2003, 9: 3–9.
43. Onofri M, Thomas A. Acute akinesia in Parkinson’s disease. Neurology, 2005, 64: 11621169.
44. Levin OS. Phenomenology and treatment of decompensation of Parkinson’s disease. Nevrol. Zhurnal, 2007, 1: 8-15.
45. Fedorova NV, Vetokhina TN. Neuroleptic extrapyramidal disorders. In the collection of works: Parkinson’s disease and movement disorders. A guide for practitioners on the materials of the II National Congress (edited by Illarioshkina SN, Levin OS). M., 2011: 275-280.
46. Pappa S, Tsouli S, Apostolou G et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol, 2010, 33: 271–275.
Review
For citations:
Poleshchuk VV, Illarioshkin SN. Amantadine in parkinson’s disease: modern possibilities of long-term therapy. Meditsinskiy sovet = Medical Council. 2018;(9):34-38. (In Russ.) https://doi.org/10.21518/2079-701X-2018-9-34-38
Views:
2080
Email this article 